- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03821636
Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients. (PRECI-Surg)
February 6, 2023 updated by: University Hospital, Lille
Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients. A Prospective, Multicentric, Randomized, Controlled Trial.
In patients with type 2 diabetes, Roux-en-Y gastric bypass (RYGB), which excludes a portion of the stomach and the proximal intestine from the alimentary circuit, improves glucose metabolism more rapidly and more extensively than is expected from weight loss.
The mechanisms of this unique effect of gastrointestinal exclusion appear to be complex and have not yet been clarified.
A recent study unveil that intestinal uptake of ingested glucose is diminished by RYGB and restricted to the common limb, where food meets bile and other digestive fluids, resulting in an overall decrease of post prandial blood glucose excursion.
the hypothesize that reducing the length of the common limb, which is rarely measured and highly variable in clinical practice, may significantly affect the metabolic outcome of gastrointestinal surgical procedures.
The aim of the present study is to compare the impact of two variants of Roux-en-Y gastric bypass with a short common limb, the long alimentary limb or the long biliary limb Roux-en-Y gastric bypass, on type 2 diabetes remission in severely obese patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
396
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amiens, France
- Recruiting
- CHU Amiens Picardie
-
Boulogne Sur Mer, France, 62321
- Recruiting
- Ch Boulogne-Sur-Me
-
Lille, France, 59037
- Recruiting
- Hop Claude Huriez Chu Lille
-
Valenciennes, France
- Recruiting
- CH de Valenciennes
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- BMI ≥ 35 kg/m2
- All patient with type 2 diabetes
- Patients who were candidates for obesity surgery in accordance with French recommendation
Exclusion Criteria:
- Severe cognitive or mental disorders
- patient who have already undergone obesity surgery
- Severe and non-stabilised eating disorders
- The likely inability of the patient to participate in lifelong medical follow-up
- Alcohol or psychoactive substances dependence
- The absence of identified prior medical management of obesity
- Diseases that are life-threatening in the short and medium term;
- Contraindications to general anaesthesia.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
SHAM_COMPARATOR: Standard Roux-en-Y
|
Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).
|
ACTIVE_COMPARATOR: Long alimentary limb Roux-en-Y
|
Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of type 2 diabetes remission
Time Frame: at 12 months after surgery
|
HbA1c < 6.5% AND fasting blood glucose < 7.0 mmol/L in absence of antidiabetic drug
|
at 12 months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute weight loss (aWL in kg)
Time Frame: at 1, 3, 6 and 12 months after surgery
|
at 1, 3, 6 and 12 months after surgery
|
|
Excess Weight Loss percentage (EWL%)
Time Frame: at 1, 3, 6 and 12 months after surgery
|
at 1, 3, 6 and 12 months after surgery
|
|
Excess BMI Loss percentage (EBL%)
Time Frame: at 1, 3, 6 and 12 months after surgery
|
at 1, 3, 6 and 12 months after surgery
|
|
Medical and surgical complication rates
Time Frame: During the month following surgery (for early complications) and from one month to 12 months postoperatively (for late complications)]
|
Medical and surgical complication rates (anastomotic leaks, biliary reflux, bowel obstruction, anastomotic ulcers, anastomotic stenosis, internal hernia, chronic gastritis, esophagitis, iron deficiency anemia)
|
During the month following surgery (for early complications) and from one month to 12 months postoperatively (for late complications)]
|
Type and severity of early and late complications for each procedure
Time Frame: During the month following surgery (for early complications) and from one month to 12 months postoperatively (for late complications)]
|
Type and severity of early and late complications for each procedure, according to the Dindo-Clavien classification
|
During the month following surgery (for early complications) and from one month to 12 months postoperatively (for late complications)]
|
Patient's quality of life score according to the Impact of Weight on Quality of Life (IWQOL) questionnaire
Time Frame: Before surgery and at 12 after surgery
|
The IWQOL questionnaire to be specifically assess the effects of obesity on health-related quality of life. The five identified scales are Physical Function, Self-Esteem, Sexual Life, Public Distress, and Work. The final 20-item IWQOL includes two primary domains: Physical (7 items) and Psychosocial (13 items) |
Before surgery and at 12 after surgery
|
Patient's quality of life score according to the Gastrointestinal Quality of Life Index (GIQLI) questionnaire adapted to bariatric surgery.
Time Frame: Before surgery and at 12 after surgery
|
GIQLI (gastrointestinal quality of life index) questionnaire.
36 questions, each containing 4 answers equating to a score ranging from 0 (least desirable answer) to 4 (most desirable answer).
Total score range 0-144.
|
Before surgery and at 12 after surgery
|
Change in glucose homeostasis
Time Frame: Before surgery and at 3, 6 and 12 months after surgery
|
glucose (mg/dl)
|
Before surgery and at 3, 6 and 12 months after surgery
|
Change in HbA1c
Time Frame: Before surgery and at 3, 6 and 12 months after surgery
|
Changes in HbA1c(%) were assessed before and after surgery
|
Before surgery and at 3, 6 and 12 months after surgery
|
Change in fasting glycemia
Time Frame: Before surgery and at 3, 6 and 12 months after surgery
|
Changes in fasting blood glucose levels (mmol/L)
|
Before surgery and at 3, 6 and 12 months after surgery
|
changes in fasting insulinemia
Time Frame: Before surgery and at 3, 6 and 12 months after surgery
|
Changes in fasting insulinemia in microunits/mL
|
Before surgery and at 3, 6 and 12 months after surgery
|
change in fasting c-peptide
Time Frame: Before surgery and at 3, 6 and 12 months after surgery
|
Changes in C-peptide(ng/ml) were assessed before and after the intervention.
|
Before surgery and at 3, 6 and 12 months after surgery
|
Number of antidiabetic treatments
Time Frame: Before surgery and at 3, 6 and 12 months after surgery
|
Metabolic profile of glucose homeostasis assessment according to antidiabetic treatments, HbA1c level, fasting glycemia, fasting insulinemia fasting c-peptide
|
Before surgery and at 3, 6 and 12 months after surgery
|
Changes in blood lipids profile
Time Frame: Before surgery and at 1, 3, 6 and 12 months after surgery
|
Changes in blood lipids profile (LDL, HDL and triglyceride concentrations) according to anitilipidemic treatments
|
Before surgery and at 1, 3, 6 and 12 months after surgery
|
change in vitamins status assessment
Time Frame: Before surgery and at 1, 3, 6 and 12 months after surgery
|
vitamines profil (vitamin B1, B9, B12, and D concentration) before and 12 and 24 months after surgery
|
Before surgery and at 1, 3, 6 and 12 months after surgery
|
change in prealbumin levels
Time Frame: Before surgery and at 1, 3, 6 and 12 months after surgery
|
Lower levels of prealbumin are associated with malnutrition.
|
Before surgery and at 1, 3, 6 and 12 months after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 16, 2019
Primary Completion (ANTICIPATED)
June 1, 2024
Study Completion (ANTICIPATED)
June 1, 2024
Study Registration Dates
First Submitted
November 26, 2018
First Submitted That Met QC Criteria
January 28, 2019
First Posted (ACTUAL)
January 30, 2019
Study Record Updates
Last Update Posted (ACTUAL)
February 8, 2023
Last Update Submitted That Met QC Criteria
February 6, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017_02
- 2017-A01761-52 (OTHER: ID-RCB number, ANSM)
- PHRCI-16-090 (OTHER: PHRC number, DGOS)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus Type 2 in Obese
-
Sahlgrenska University Hospital, SwedenKarolinska Institutet; Imperial College London; University Hospital, Ghent; Universitair... and other collaboratorsCompletedDiabetes Mellitus Type 2 in ObeseSpain, Sweden, Belgium, United Kingdom
-
University of OxfordSecond NatureActive, not recruitingType 2 Diabetes Mellitus in ObeseUnited Kingdom
-
University of NottinghamMedical Research CouncilRecruitingType 2 Diabetes Mellitus in ObeseUnited Kingdom
-
NovMetaPharma Co., Ltd.CompletedDiabetes Mellitus Type 2 in ObeseUnited States
-
Hasan Kalyoncu UniversityRecruitingDiabetes Mellitus Type 2 in ObeseTurkey
-
Region StockholmRecruitingDiabetes Mellitus Type 2 in ObeseSweden
-
tarek mahdyCompletedDiabetes Mellitus Type 2 in Obese
-
Beijing Chao Yang HospitalCompleted
-
Chinese University of Hong KongCompleted
-
Radboud University Medical CenterNot yet recruitingDiabetes Mellitus Type 2 in ObeseNetherlands
Clinical Trials on Standard Roux-en-Y gastric bypass
-
CARLOS ZERRWECK LOPEZCompletedRoux-en-Y Gastric Bypass | Bariatric Surgery | Metabolic SurgeryMexico
-
Centro Universitário de AnapolisIrmandade da Santa Casa de Misericordia de Sao Paulo; Clínica de Gastroenterologia... and other collaboratorsUnknownMorbid Obesity | Severe ObesityBrazil
-
CARLOS ZERRWECK LOPEZCompletedObesity | Bariatric Surgery Candidate | Type2 Diabetes | Laparoscopic Gastric BypassMexico
-
Spital Limmattal SchlierenUnknownObesity | Bypass ComplicationsSwitzerland
-
Instituto Nacional de Ciencias Medicas y Nutricion...Completed
-
Hvidovre University HospitalUnknownObesity | Bone Loss | Gastric Bypass SurgeryDenmark
-
Hospital Universitario Virgen de la ArrixacaUnknown
-
University of Roma La SapienzaCompleted
-
Marco BueterDr. Alan Spector, Florida State University, Department of PsychologyCompletedObesity | Bariatric Surgery | Ingestive Behavior | Food Deprivation | Roux-en-y Gastric Bypass | Ingestive Microstructure | DrinkometerSwitzerland
-
Marco BueterDepartment of Psychology and Program in Neuroscience, Florida State University...CompletedDrinking Behavior | Obesity, Morbid | Bariatric Surgery | Food Deprivation | Roux-en-y Gastric Bypass | Ingestive Microstructure | Drinkometer | MealSwitzerland